DNTH
Dianthus Therapeutics Inc

1,238
Mkt Cap
$1.98B
Volume
870,128.00
52W High
$46.59
52W Low
$13.37
PE Ratio
-12.60
DNTH Fundamentals
Price
$44.00
Prev Close
$46.29
Open
$46.29
50D MA
$40.93
Beta
0.95
Avg. Volume
647,637.41
EPS (Annual)
-$2.55
P/B
3.45
Rev/Employee
$79,935.90
Loading...
Loading...
News
all
press releases
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.1% - Should You Sell?
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 6.1% - Should You Sell...
MarketBeat·11h ago
News Placeholder
More News
News Placeholder
Truist Financial Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $63.00
Truist Financial boosted their target price on Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a "buy" rating in a research report on Thursday...
MarketBeat·8d ago
News Placeholder
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Moderate Buy" by Analysts
Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the firm, MarketBeat...
MarketBeat·10d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.3% - What's Next?
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.3% - What's Next...
MarketBeat·14d ago
News Placeholder
Dianthus Therapeutics, Inc. $DNTH Stake Lessened by Moody Aldrich Partners LLC
Moody Aldrich Partners LLC decreased its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 40.9% during the third quarter, according to its most recent Form 13F filing...
MarketBeat·14d ago
News Placeholder
Wedbush Reiterates Outperform Rating for Dianthus Therapeutics (NASDAQ:DNTH)
Wedbush restated an "outperform" rating and set a $46.00 target price on shares of Dianthus Therapeutics in a report on Monday...
MarketBeat·25d ago
News Placeholder
Dianthus Therapeutics, Inc. $DNTH Shares Sold by 5AM Venture Management LLC
5AM Venture Management LLC cut its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 4.2% during the second quarter, according to the company in its most recent filing...
MarketBeat·1mo ago
News Placeholder
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Brokerages
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has earned an average rating of "Moderate Buy" from the ten analysts that are currently covering the firm, Marketbeat reports. One analyst...
MarketBeat·1mo ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) CFO Ryan Savitz Sells 20,000 Shares
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) CFO Ryan Savitz sold 20,000 shares of the company's stock in a transaction on Thursday, December 4th. The stock was sold at an average...
MarketBeat·1mo ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) CFO Sells $903,600.00 in Stock
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction on Thursday, December 4th. The shares were sold at an...
MarketBeat·1mo ago
<
1
2
...
>

Latest DNTH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.